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Background and aims
Anti-idiotypic antibodies (Abs) represent an alternative
vaccination approach in human therapy. This approach
is based on the idiotype (Id) network theory postulated
by Jerne describing the Ab (Ab1) – anti-idiotypic Ab
(Ab2) – anti-anti-idiotypic Ab (Ab3) cascade stimula-
tion. Specific anti-Id Abs serve as an “internal image” of
the target antigen and can be used to induce Abs able
to bind to the cognate antigen [1]. The anti-Id Ab Ab2/
3H6 [2], developed at our Institute was generated in
mouse and is directed against the human monoclonal
Ab (mAb) 2F5, which broadly and potently neutralizes
primary HIV-1 isolates [3]. Ab2/3H6 which has been
characterized previously [4,5] is able to mimic the anti-
gen recognition site of 2F5 and therefore it is suggested
as a putative candidate for an HIV-1 vaccine.
We investigated the potential of Ab2/3H6 by immuni-
zation of Fab fragments and fusion proteins with inter-
leukin 15 (IL15) and tetanus toxin (TT) tags as immune
modulators. After three prime/boost administrations
rabbit sera were purified and analyzed for 2F5-like spe-
cific Abs. Further, the 2F5-like Abs from the sera were
enriched by affinity purification and characterized for
their binding affinity to 2F5.
In an additional approach we applied different huma-
nization methods to reduce the immunogenicity of the
originally mouse derived Ab2/3H6. The mouse variable
regions of Ab2/3H6 were subjected to three different
humanization methods, namely resurfacing, CDR-graft-
ing and superhumanization. Four differently humanized
Ab2/3H6 variants were characterized for their binding
affinity to 2F5 in comparison to the original Ab2/3H6.
Results
To evaluate the humoral immune response of Ab2/3H6
we designed Ab2/3H6Fab fusion proteins with IL15 and
TT. Recombinant CHO cell lines were established and
after protein purification New Zealand white rabbits
were immunized with the Ab2/3H6Fab variants. Ten
days after the final boost sera were collected and ana-
lyzed for total rabbit IgG levels. After proteinA affinity
purification of the sera the isolated rabbit IgGs were
tested for Ab2/3H6Fab and recombinant gp140 (UG37)
specificity (Figure 1A). Further an affinity enrichment
step using a UG37/ELDKWA column was performed
and the obtained Ab3 fraction was tested on UG37 (Fig-
ure 1B) and additionally on the original 2F5 epitope
ELDKWA (Figure 1C). Finally the Ab3 fraction was
tested for binding affinity to the UG37 in a bio-layer
interferometry assay which showed that the Ab3 fraction
has a 6.6 fold reduced affinity towards UG37 compared
to the mAb 2F5 (Table 1).
For the humanization approach three different meth-
ods were chosen. The “resurfaced” variant (RS3H6) was
developed by a computer model and surface exposed
amino acids in the murine framework (FR) were substi-
tuted by residues usually found at equivalent positions
in human Abs. The “superhumanized” form (SH3H6)
was designed by structural homologies between the
murine Ab2/3H6 CDRs and human germline CDRs.
The most homologous human germline Ab was then
used as acceptor FR. For the “CDR-grafted” variant two
versions were expressed. An “aggressive” graft (GA3H6)
harbouring less backmutations, making the grafted Ab
more human-like and a “conservative” graft (GC3H6)
with more backmutations. The different “reshaped” vari-
able regions of Ab2/3H6 were expressed in CHO-cells
as IgG1 molecules. The obtained “humanized” Ab var-
iants were further characterized by competition ELISA
(Figure 1D).
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RS3H6 and GC3H6 showed a nearly identical slope of
a concentration dependent 2F5 inhibition compared to
the chimeric (ch) 3H6. RS3H6, GC3H6 or ch3H6 com-
plexed 50 % of mAb 2F5 with a five fold molar excess.
GA3H6 was able to bind 50 % of 2F5 in a 15 fold
excess. In contrast, SH3H6 did not interact with 2F5
even in an 80 fold excess which is comparable to the
negative control (unspecific IgG). The ELISA results
were supported by binding affinity experiments with 2F5
in a bio-layer interferometry assay: RS3H6, GC3H6 and
Figure 1 (A) Binding of purified rabbit IgGs immunized with different Fab preparations and control (pre-immun IgG fraction) to Ab2/3H6Fab
and recombinant HIV-1 gp140 (UG37); (B) Binding of the Ab3 (2F5-like) Ab fraction purified from pooled rabbit IgG fractions to recombinant
HIV-1 gp140 (UG37) and (C) synthetic 2F5 epitope (ELDKWA); (D) Competition ELISA. Biotinylated 2F5 (2F5-B) was allowed to complex with serial
dilutions of Ab2/3H6 mutants and afterwards uncoupled 2F5-B was determined on an epitope pre-coated ELISA plate. The optical density
resulting from binding of 2F5-B to the synthetic epitope GGGELDKWASL is plotted versus the logarithm of the concentration of Ab2/3H6
mutants.
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ch3H6 have similar binding affinity to 2F5 whereas
GA3H6 has a 2-fold reduction in affinity.
Discussion and conclusion
The Ab2/3H6 was generated to be used as an HIV-1
vaccine, based on the induction of 2F5-like Abs (Ab3s).
First we did a “proof of concept” and immunized rabbits
with different Ab2/3H6Fab fusion proteins to induce
2F5-like Abs. Immunochemical analyses showed that the
use of IL15 and TT as immune modulators do not sig-
nificantly enhance total rabbit IgG levels or the produc-
tion of Ab2/3H6Fab specific Abs. However it could be
demonstrated that UG37 binding Abs (Ab3s) were
induced significantly (Figure 1A). Quantification of var-
ious purification steps revealed that only 0.7 % of the
rabbit IgG fraction contained UG37/ELDKWA binding
Abs. This affinity enriched Ab3 fraction shows signifi-
cant binding to UG37 and reduced binding to the syn-
thetic 2F5 epitope ELDKWA in ELISA (Figure 1B/C).
Affinity binding studies showed that the obtained Ab3
fraction has only a 6.6-fold lower affinity to the recom-
binant UG37 protein compared to 2F5 (Table 1).
In a next step different humanization methods were
evaluated. The “resurfaced” and the “conservative”
grafted variants showed similar binding properties to
2F5 as the original Ab2/3H6 version, while the “aggres-
sively” grafted Ab had a 2-fold lower affinity and the
“superhumanized” form completely lost the ability to
bind to 2F5.
We postulate that after humanizing the framework
regions of Ab2/3H6 the immune response will be
focused towards the paratope of the Ab2 and therefore
enhance elicitation of Ab3 when administered during
human therapy. Therefore affinity to 2F5 is not the cru-
cial factor in evaluating the best candidate for a clinical
study. Our results show that the Ab2/3H6 variants
RS3H6 and GA3H6 would be suitable candidates for
future studies.
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Table 1 Summary of k-values for binding to UG37
Samples [c=400nM] kon [1/Ms] koff [1/s] KD [nM]
mAb 2F5 1.66 x1004 3.09 x10-04 18.65
Ab3 fraction 1.56 x1004 1.91 x10-03 122.90
Control IgG fraction n.d. n.d. n.d.
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